Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NOVADEL PHARMA INC (NVDL)
|
Add to portfolio |
|
|
|
| Price: |
$0.01
| | Metrics |
| OS: |
134.9
|
M
| |
|
|
| Market cap: |
$1.08
|
M
| |
|
|
|
Net cash:
|
$429
|
k
| |
$0.00
|
per share
|
|
EV:
|
$650.1
|
k
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Jul-31-06 | Dec-31-05 | Jul-31-05 | Jul-31-04 |
| Revenues | 0.4 | 0.4 | 0.5 | 3.3 | 1.9 | 2.1 | 0.4 | 0.5 |
| Revenue growth | 16.9% | -23.0% | -85.7% | 58.7% | 330.5% | | -5.8% | |
| Cost of goods sold | 4.4 | 5.1 | 6.8 | 7.0 | 7.2 | 3.1 | 6.4 | 4.6 |
| Gross profit | -4.0 | -4.7 | -6.3 | -3.7 | -5.3 | -1.1 | -6.0 | -4.2 |
| Gross margin | -949.5% | -1305.3% | -1346.1% | -112.0% | -279.8% | -51.1% | -1355.8% | -892.9% |
| Selling, general and administrative | 6.5 | 9.0 | 18.7 | 13.5 | 12.5 | 6.5 | 10.2 | 7.1 |
| Research and development | 2.5 | 3.9 | 11.9 | 6.6 | 5.3 | 3.4 | 3.8 | 2.5 |
| EBIT | -6.1 | -8.2 | -18.2 | -10.3 | -10.6 | -4.5 | -9.8 | -6.7 |
| EBIT margin | -1444.3% | -2282.3% | -3877.8% | -312.9% | -558.9% | -215.4% | -2227.3% | -1427.7% |
| Pre-tax income | -8.6 | -10.3 | -17.6 | -9.9 | -10.3 | -4.3 | -9.7 | -6.6 |
| Income taxes | -1.1 | -0.7 | -0.7 | -0.5 | -0.3 | -0.5 | -0.2 | -0.2 |
| Tax rate | 12.2% | 7.1% | 3.7% | 4.7% | 2.5% | 10.9% | 2.5% | 3.3% |
| Net income | -7.6 | -9.6 | -17.0 | -9.5 | -10.1 | -3.8 | -9.5 | -6.3 |
| Net margin | -1795.5% | -2655.4% | -3616.8% | -288.4% | -533.5% | -184.1% | -2152.6% | -1360.7% |
| |
| Diluted EPS | ($0.12) | ($0.16) | ($0.29) | ($0.20) | ($0.23) | ($0.08) | ($0.27) | ($0.24) |
| Shares outstanding (diluted) | 61.3 | 59.6 | 59.5 | 46.7 | 43.0 | 49.5 | 34.8 | 26.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|